Prescott v. TC Heartland, LLC

Background

This putative class action concerns TC Heartland’s marketing and labeling of Splenda products. Steven Prescott, Richard Tilker, Samuel Garcia, and Rochelle Wilson alleged that TC Heartland marketed Splenda to health-conscious consumers, including people with Type 2 diabetes, as a sugar alternative with health benefits. They challenged statements including “help manage blood sugar,” “diabetes care,” “the #1 recommended brand by doctors and dietitians,” and “suitable for people with diabetes.”

The plaintiffs alleged that these statements were false or misleading because Splenda’s primary ingredient, sucralose, allegedly does not provide the represented benefits and may harm people with diabetes. They cited scientific studies and a World Health Organization report. The court did not decide whether sucralose actually causes the alleged health effects.

The plaintiffs asserted five types of claims: violations of California’s Consumer Legal Remedies Act, False Advertising Law, and Unfair Competition Law; breach of warranty; and unjust enrichment and restitution. The first three claims were brought for a California subclass, while the warranty and unjust-enrichment claims were brought for a proposed nationwide class and the California subclass. The plaintiffs sought monetary relief and injunctions against the allegedly deceptive labeling. They also requested an injunction requiring TC Heartland to conduct an affirmative advertising campaign to correct what they described as public misperceptions.

TC Heartland’s Motion

TC Heartland moved to dismiss under Federal Rule of Civil Procedure 12(b)(6), which tests whether a complaint adequately states a legal claim. It argued that the claims were preempted by the FDA’s 1999 determination that sucralose could be used as a general-purpose sweetener. TC Heartland also argued that the plaintiffs lacked Article III standing because they alleged no physical injury, that the labels were not likely to mislead reasonable consumers, and that the requested corrective advertising campaign would violate the First Amendment.

Federal Preemption

The court rejected TC Heartland’s argument that the FDA’s approval of sucralose preempted the plaintiffs’ state-law claims. The court distinguished between the FDA’s determination that sucralose is generally safe and the plaintiffs’ allegation that TC Heartland made specific health-benefit claims about Splenda for people with diabetes.

The court concluded that deciding whether statements such as “suitable for people with diabetes,” “diabetes care,” and “help manage blood sugar” were misleading would not conflict with the FDA’s general safety determination. The court also held that the plaintiffs’ deceptive-labeling claims were not preempted because they paralleled federal regulations requiring health claims on food labels to be complete, truthful, and not misleading.

Article III Standing

Article III standing requires an injury, a connection between the injury and the challenged conduct, and a likelihood that the requested relief can address the injury. The court held that the plaintiffs adequately alleged an economic injury. They alleged that they would not have purchased the Splenda products, or would have paid significantly less for them, if they had known that the label claims were false or misleading.

The court therefore rejected TC Heartland’s argument that the absence of physical injury defeated standing. It concluded that the alleged economic loss was sufficient to allow the plaintiffs to bring the lawsuit at this stage.

Whether the Labels Were Plausibly Misleading

The court held that the plaintiffs adequately pleaded that TC Heartland’s health claims could mislead reasonable consumers. Under the reasonable-consumer test, a plaintiff must show that a significant portion of reasonable consumers, including targeted consumers, would likely be misled by the challenged representation.

The court reasoned that words such as “care” and “help” could imply that Splenda had a therapeutic effect or would provide a health benefit to people with diabetes. The court also emphasized that the plaintiffs did not need to prove at the pleading stage that sucralose was unsafe. They needed only to plausibly allege that the labels could lead reasonable consumers to believe that Splenda would improve diabetes or help control blood sugar.

The court declined to resolve the parties’ factual disagreement over the scientific studies or the health risks of sucralose. It determined that the differing interpretations of the labels presented a factual dispute that was not appropriate for resolution on a motion to dismiss. The court therefore denied dismissal of the plaintiffs’ labeling-based claims.

Corrective Advertising Request

The plaintiffs sought an injunction requiring TC Heartland to conduct an affirmative advertising campaign to dispel alleged public misperceptions about Splenda. TC Heartland argued that compelling this speech would violate the First Amendment.

The court agreed. It explained that compelled speech is generally prohibited and that compelled commercial speech is allowed only in narrower circumstances, including when the required speech consists of purely factual and uncontroversial information. The court concluded that an advertising campaign about the risks of sucralose could not be treated as purely factual and uncontroversial, particularly because the FDA had determined that sucralose was generally safe.

Disposition

The court denied TC Heartland’s motion to dismiss except as to the plaintiffs’ request for injunctive relief requiring an affirmative advertising campaign. As to that request, the court granted TC Heartland’s motion to dismiss.